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Abstract 
Purpose: This study aims to assess inappropriate prescribing (IP) to elderly patients during the month prior to 
hospitalization and to compare different IP criteria.   
Methods: An observational, prospective and multicentric study was carried out in the internal medicine services 
of seven Spanish hospitals. Patients aged 75 years and older were randomly selected after hospital admission for 
a year. To assess potentially inappropriate medicines (PIMs), the Beers and STOPP criteria were used and to 
assess Potentially Prescribing Omissions (PPOs), the START criteria and ACOVE-3 medicine quality indicators 
were used. An analysis to assess factors associated with IP was performed.  
Results: 672 patients [median age (Q1_Q3) 82 (79-86) years, 55.9% female] were included. Median prescribed 
medicines in the month prior to hospitalization were 10(Q1-Q3 7-13). The prevalence of IP was 87.6%, and 
54.3% of patients had PIMs and PPOs concurrently. A higher prevalence rate of PIMs was predicted using the 
STOPP criteria than with the Beers criteria (p<.001) and a higher prevalence of PPOs using the ACOVE-3 
criteria than using the START criteria (p<.001) was observed. Polypharmacy (≥10 medicines) was the strongest 
predictor of IP [OR=11.34 95% confidence interval (CI) 4.96-25.94], PIMs [OR=14.16, 95% CI 6.44-31.12], 
Beers-listed PIMs [OR=8.19, 95% CI 3.01-22.28] and STOPP-listed PIMs [OR=8.21, 95% CI 3.47-19.44]. PIMs 
was the strongest predictor of PPOs [OR=2.79, 95% CI 1.81-4.28]. 
Conclusions: A high prevalence of polypharmacy and PIMs and PPOs were reported. More than half the 
patients had simultaneous PIMs and PPOs. The related factors to PIMs and PPOs were different.  
 
Keywords: polypharmacy, older multimorbidity patients, inappropriate prescribing, potentially inappropriate 
medicines, potentially prescribing omissions.
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Introduction 
 
Inappropriate prescribing (IP) to older people can be defined as a situation in which pharmacotherapy is not 
within accepted medical standards. This can include overprescribing, misprescribing, and underprescribing [1-5].  
 
Different criteria have been developed to identify the appropriate use of medicines in people ≥65 years old. 
Some are based on clinical judgements (implicit criteria) and others, the most widespread, on predetermined 
standards (explicit criteria). The explicit criteria include Potentially Inappropriate Medicines (PIMs) that should 
be avoided in any circumstances and drugs that should be avoided in patients with specific disorders [1, 6-8]. 
The most widely disseminated are the Beers [9, 10] and the STOPP (Screening Tool of Older Person's 
Prescriptions) criteria [11]. The prevalence of PIMs described in the studies range from 25% to 75% of patients 
and polypharmacy is the main factor associated with PIMs [12-14].  
 
 The criteria for IP of medicines in older people focusing on the detection of underprescribing or Potentially 
Prescribing Omissions (PPOs) are more recent.  The START (Screening Tool to Alert doctors to Right 
Treatment) criteria are a new tool in screening for PPOs in the elderly population, and the published results 
indicate a very high prevalence, between 51 and 72% of patients [13, 15].  
 
Also for the most vulnerable older people, some health care quality indicators (Assessing Care of Vulnerable 
Elders - ACOVE) have been identified in recent years. The ACOVE project approach is more comprehensive as 
it includes pharmacologic care indicators [16, 17]. Studies in the United States, focusing on the ACOVE 
pharmacologic care indicators, show that underprescribing indicators get the worst results, affecting 50% of 
patients [18].     
  
The objectives of the study were to analyze medicine consumption and inappropriate use of medications the 
month prior to hospital admission in medical units in older patients; to compare different tools of inappropriate 
prescribing focusing on PIMs (STOPP and Beers criteria) and PPOs (START criteria and ACOVE 
underprescribing indicators), and to explore factors associated with inappropriate use of medicines. 
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Methods 
 
An observational, prospective, multicentric study of a cohort of patients hospitalised in the Internal Medicine 
Services of seven Spanish hospitals was carried out for a year (from April 2011 to March 2012). 
 
Patients, 75 years or older, admitted with an acute illness or an exacerbation of a chronic condition who signed 
the informed consent, were included. Hospital admission was through either the emergency department or 
directly from primary care. Patients with a scheduled or a short-duration (less than 24 hours) admission, those 
seen as an outpatient by the researcher, and those where no access was available to primary care medical 
information, were excluded from the study.  
 
Information on a patient's variables was obtained from the hospital and the primary care electronic medical 
records and from interviews with the patients and/or relatives, using a structured questionnaire. On admission, 
data about patient's age, gender, and social characteristics such as residence (home, nursing home or another 
hospital) and living conditions (single, with a partner or relative or other), and frequency of health care services 
utilization (number of visits to general practitioner or hospital admissions) for one month prior to admission, was 
collected.  
 
In addition, information on activities of daily living, basal (one month previous to admission) and on admission 
(during the first 48 hours), using the Barthel index [19], cognitive function using the Pffeifer scale [20] and the  
Global Deterioration Scale (GDS) [21], specific diagnosis and cumulative multimorbitity as quantified by the 
Charlson Co-morbidity index [22] and the polypathological patient scale [23], number of falls in the preceding 3 
months and delirium during the first 48 hours of admission using the Confusion Assessment Method [CAM] [24], 
was assessed. On discharge, data about fate on discharge (home, nursing home, or another hospital) and the 
Barthel index score were obtained. 
 
Regarding medicine exposure, information on the number, type, dosage and duration of prescription medicines 
in the preceding month before admission was obtained using a complete pharmacological anamnesis. This 
consisted of an open question asking patients or their relatives, in the case of cognitively impaired patients, about 
medicine exposure for one month before admission, followed by several questions about medicine exposure for 
common symptoms and conditions frequently treated with medicines. Information from the primary care 
electronic medical record was used to complete the data. In case of conflict regarding medication information, 
patient or caregiver data was considered to be the main information. Medicines were classified according to the 
Anatomical Therapeutic classification system (ATC). 
  
Beers [9], STOPP and START criteria [11, 15, 25] and ACOVE-3 underprescribing indicators for chronic 
conditions were applied to each dataset on admission. The ACOVE 3 contains a total of 26 chronic conditions 
and 392 quality indicators [16, 17].  Of these, 142 quality indicators pertained to pharmacologic care. Following 
the methodology used in other studies [18], the pharmacologic indicators were stratified into 4 domains:  
“prescribing indicated medications” with 68 indicators, “avoiding inappropriate medications” with 19 indicators, 
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“education, continuity, and documentation” with 43 indicators and “monitoring” with 12 indicators. Finally, 11 
out of the total 26 conditions, and their corresponding 37 quality indicators from the prescribing indicated 
medications domain were selected for the study (see Appendix 2 on the online material only). To choose these 
eleven chronic conditions from ACOVE 3, the prevalence of the conditions in the elderly, the number of the 
quality pharmacologic indicators of the condition and finally, the similitude with other underprescribing tools 
such as the START criteria were taken into account. Four researchers (a geriatrician, a medical internist and two 
clinical pharmacologists with experience in geriatric assessment and prescribing medicines to elderly patients) 
independently selected the ACOVE 3 chronic conditions and the underprescribing indicators for the study. 
Differences were resolved by consensus [26].  A good level of inter-rater reliability has been described for the 
Beers, the STOPP/START criteria and the underprescribing ACOVE indicators [13, 26, 27].  All the 
interviewers were consultants or nurses trained in geriatric assessment and in the use of inappropriate prescribing 
criteria. 
 
In the study, global IP was considered when at least one Beer’s, STOPP, START and/or ACOVE criteria was 
present. Global PIM was considered when at least one Beers and/or STOPP criteria was prescribed, and global 
PPO, when at least one START and/or ACOVE-3 criteria was omitted, Beers-listed PIM, when at least one of 
the Beers criteria was prescribed, STOPP-listed PIM, when at least one STOPP criteria was prescribed, START-
listed PPO, when at least one START criteria was omitted, and ACOVE3-listed PPO, when at least one 
ACOVE3 criteria was omitted.  
 
The study was conducted according to international ethical recommendations in accordance with the national 
directives in relation to post-authorization studies. The study was approved by the Ethics Committee of Clinical 
Investigation in each participating hospital. 
 
Sample size and sampling method  
 
A sample of around 400 patients must be included to estimate 50% of inappropriate prescribing with a precision 
of ± 5% (95% confidence limits). To obtain enough information on the different age groups, around 700 patients 
had to be included, 350 of whom were ≥75 to 84 years old and 350 ≥85 years old. To fit the calculated sample 
size, each hospital included 2 patients per week (one in each age group) admitted with the inclusion criteria. 
Patients were selected randomly every week on consecutive days from the hospitalization lists.  
 
Statistical analysis 
 
Since the study design oversampled the proportion of older patients, and the number of eligible patients was 
different for the participating centres, analyses were weighted by age distribution and frequency of the eligible 
population in each hospital. To examine the association between inappropriate prescribing and potential risk 
factors, a multivariate logistic regression analysis was performed where an inappropriate prescribing indicator 
was the dependent variable and sociodemographic variables, multimorbidity (≥2 clinical categories of the 
Polypathological Patient scale)[23] and geriatric conditions, and number of prescription medicines in the 
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preceding month before hospitalization were the independent variables. The adjusted Odds ratio (OR) with its 
95% confidence intervals (CI) was calculated. Significance was set at a level of 0.05, and was two-tailed. 
Statistical analysis was performed using the procedures for complex surveys of the SAS 9.2 program (SAS 
Institute Inc., Cary, NC, USA). 
7 
 
 
Results 
A total of six hundred and seventy-two patients were included in the study, with a median (Q1-Q3) age of 82 
(79-86) years, and 55.9% were female. Table 1 shows the main baseline characteristics of the study population. 
The most frequent chronic conditions were arterial hypertension (78.3% of patients), heart failure (42.8%), 
chronic obstructive pulmonary disease (31%), diabetes mellitus (30.9%), cerebrovascular disease (27.2%) and 
dementia (18.4%). Sixty percent of patients were independent or slightly dependent for activities of daily living 
according to the Barthel index. The baseline cognitive function was normal (Reisberg of 1 or 2) in 57.4% of 
patients and 52.7% out of 565 had a normal cognitive performance on admission according to the Pfeiffer test.  
 
Median prescribed medicines during the month prior to admission was 10 (Q1-Q3 7-13) per patient; between 0 
and 4 medicines were prescribed to 7.6% of patients, between 5 and 9 to 36.5% and ten or more to 55.9%. 
Omeprazole (61.1% of patients), acetaminophen (47.3%) and furosemide (45.2%) were the most frequently 
prescribed medicines and by subgroups the most frequently prescribed were agents for acid related disorders 
(76.8%), followed by antithrombotic agents (67.1%) and diuretics (66.2%). 
  
Distribution of patients into the groups of IP is shown in figure 1. The global IP prevalence rate was 87.6% and 
most patients (54.3%) had concurrent global PIMs and global PPOs. Using the STOPP criteria, the PIMs 
prevalence rate was higher (61.3%) than using the Beer's criteria (51.1%) (Difference = 10.3%, 95% CI 5.7%-
14.8%, p<.001), and using the ACOVE criteria, the PPO prevalence rate was also higher (56.5%) than using the 
START criteria (51.3%) (Difference = 5.2%, 95% CI, 1.3%-9.1%, p<.001).  
 
The most frequently found PIMs according to the Beers' criteria was the use of long-acting benzodiazepines 
(11.8%) independent of diagnoses or conditions, and the prescription of short to intermediate-acting 
benzodiazepines and tricyclic antidepressants to patients with previous falls or syncope (9.9%). The most 
commonly encountered STOPP criteria included use of benzodiazepines to patients who are prone to falls 
(15.0%) and the use of long-term long-acting benzodiazepines (11.5%). Among the START criteria the most 
frequently identified PPOs were ACE inhibitors to patients with heart failure (15.0%) and oral anticoagulation in 
the presence of chronic atrial fibrillation (11.5%). The most commonly identified PPOs by the ACOVE criteria 
were ACE inhibitors or angiotensin-receptor blockers to patients with hypertension and comorbid vascular 
diseases (10.8%), and oral anticoagulation to patients with chronic atrial fibrillation who are at medium to high 
risk of stroke (9.0%) (Table 2).   
 
Prescription of ten or more medicines was the strongest independent risk factor associated with global IP and 
global PIM (OR= 11.34, 95% CI, 4.96-25.94 and OR= 14.16, 95% CI, 6.44-31.12, respectively) (Table 3). 
Global PIM (OR= 2.79, 95% CI, 1.81-4.28) was the strongest independent predictor of global PPO (Table 3). 
 
When independent risk factors associated with the different criteria of IP were analysed a prescription of ten or 
more medicines was the strongest predictor of PIM according to the Beer’s and the STOPP criteria (OR= 8.19, 
95% CI, 3.01-22.28 and OR= 8.21, 95% CI, 3.47-19.44, respectively) (Table 4). The strongest independent 
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predictors of PPO according to the START criteria were non-community dwelling (OR= 1.82, 95% CI, 1.02-
3.24) and multimorbidity (OR= 1.76, 95% CI, 1.14-2.7), and identification of at least one STOPP-listed criteria 
was the independent risk factor of PPO according to the ACOVE 3 (OR=2.3, 95% CI, 1.51-3.49) (Table 4). 
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Discussion 
 
This study focused on a comprehensive assessment of IP in older patients using different tools of PIMs as well 
as PPOs. In our study the prevalence of polypharmacy and the prevalence of PIMs and PPOs were high and a 
large proportion of patients had PIMs and PPOs concurrently according to the used instruments. In addition, a 
higher prevalence rate of PIMs was predicted using the STOPP criteria than with the Beers criteria and a higher 
prevalence of PPOs using the ACOVE-3 criteria than using the START criteria was observed. 
 
The study population was a group of very elderly patients who were mostly admitted through the emergency 
department with an acute illness or an exacerbation of a chronic condition and most of them came from home. 
They had a significant multimorbidity, mild dependence for basic activities of daily living and a good baseline 
cognitive performance. Most of them were discharged and went home. In our study, polypharmacy was higher 
than that described in other studies focusing on patients’ medicine consumption on hospital admission [11, 13, 
28]. However, an exhaustive pharmacology anamnesis study was carried out in our study analysing the 
consumption of drugs the month before admission, not only at the time of admission, as well as  a complete 
review of drug utilization from the primary care and hospital electronic medical records, and performing an 
exhaustive drug interview of patients and/or relatives. This can explain, at least in part, the differences in 
comparison with other studies.   
 
Almost ninety percent of patients were prescribed at least one global IP criteria. Our results also showed that 
more than half of our study population had simultaneous global PIM and global PPO criteria. Finally, when PIM 
or PPO was independently analyzed using the different listed criteria, a very high rate of PIM and PPO was 
encountered in each one. These rates are slightly higher than those described in a recent European multicentric 
study [13].This comprehensive analysis of global IP has allowed us to show the complexity of medicines 
prescribed to the elderly.  As in most of our study population, polypharmacy and prescription of global PIM and 
global PPO concurred. A study showed that more than 40% of patients with polypharmacy had both PIM and 
PPO and that the risk factors associated with PIM differed to those associated with PPO [5]. 
  
In other series, the use of benzodiazepines has also been the most common described PIM, although with  lower 
percentages [11, 13]. In another recent study, the use of proton pump inhibitors was the most frequently 
described PIM according to the STOPP criteria [14]. Regarding the PPO, our results are similar to those reported 
in other studies albeit the omission rate of ACE inhibitors or angiotensin receptor blockers and of oral 
anticoagulants was higher in our study and it was lower than that of calcium or vitamin D and of statins [13]. 
  
In our study, polypharmacy was the strongest independent predictor of global IP, global PIM, Beer’s-listed PIM 
and STOPP-listed PIM criteria. Other strong predictors were female gender for global IP, global PIM and 
Beer’s-listed PIM criteria and, total dependence on basal activities of daily living for only global PIM and 
STOPP-listed PIM criteria. Polypharmacy and female gender have been described as PIM prescription predictors 
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in other studies [5, 11, 13, 29] as well as other factors such as a history of falls that have not appeared in our 
study [29]. The association between total dependence on activities of daily living and PIM prescription is a novel 
finding requiring evaluation in further studies. A recent study showed a high prevalence of PIM prescription 
according to the STOPP criteria in nursing homes, and one third of these prescribed medicines were central 
nervous system acting drugs [30]. The inverse association between multimorbidity and STOPP-listed PIM is 
noteworthy, but a plausible interpretation is that multimorbidity might be associated with a more appropriate 
polypharmacy.  
 
 
In our study, the strongest independent predictor of global PPO was global PIM. This association and that of 
ACOVE3- listed PPO with STOPP-listed PIM may be due to the fact that most patients in the study had 
simultaneous potentially inappropriate medicines and potentially prescribing omissions. This is an interesting 
data that need to be confirmed in further studies. Independent predictors of START-listed PPO criteria were 
multimorbidity and an origin other than home. PPO predictors described in other studies according to the 
START criteria have been aged over 85 years [13, 15], female gender [15], and multimorbidity [13].  
 
In the present study, the ACOVE-3 criteria were a good screening PPO instrument, and a higher PPO prevalence 
was encountered in comparison to the START criteria. Our results should lead to these criteria being used as a 
screening instrument for PPO. The high percentages of underprescribing of medicines reported in our study and 
others should be viewed with caution in as much as these criteria have been developed by expert groups based on 
their experience and scientific evidence. The lack of high quality evidence in the treatment of major chronic 
diseases in elderly patients with multimorbidity is well known [29,31,32].  
 
This study has some limitations. Firstly, there is no previous experience in the use of the ACOVE medication 
quality indicators on the detection of PPO. However, given the lack of criteria for underprescribing in the 
elderly, and the comprehensive pharmacological approach of the ACOVE project, especially focusing on 
underprescribing, we considered it of interest to select these quality indicators and make the comparison with the 
START underprescribing criteria. Secondly, a previous version of the Beers criteria, which was the latest 
currently available, has been used in our study, and our results should be confirmed by using the most recently 
published version [10]. 
 
In conclusion, with the comprehensive analysis of IP in older people done in our study using different 
instruments on hospital admission a high prevalence of polypharmacy and a high prevalence of PIMs and PPOs 
were reported. In most of our population both PIMs and PPOs were simultaneously identified. The kind of PIMs 
and PPOs and even the associated factors were similar to those reported in other studies. More studies focusing 
on inappropriate prescription instruments in older people and especially in multimorbidity older people, are 
needed.   
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Conclusions or key points:  
• More than half of our study population had simultaneous potentially inappropriate medicines and 
potentially prescribing omissions. 
• A higher prevalence rate of PIMs was predicted using the STOPP criteria than with the Beers criteria 
and a higher prevalence of PPOs using the ACOVE-3 criteria than using the START criteria was 
observed.The risk factors associated to potentially inappropriate medicines differed to those 
associated with potentially prescribing omissions. 
• Pharmacologic care indicators focused on prescribing indicated medications of the ACOVE 3 can be 
considered a useful tool in detecting underprescribing in the elderly. 
 
Learning points:  
• Polypharmacy among older people is prevalent and it is associated with a high prevalence of potentially 
inappropriate medicines.   
• More studies are needed to better know the factors associated with potentially prescribing omissions.  
• A high proportion of older people may simultaneously have potentially inappropriate medicines and 
potentially prescribing omissions. 
• Prescribing indicated medications of the ACOVE 3 can be considered a useful tool in detecting 
underprescribing in the elderly. 
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Table 1 Baseline characteristics of patients (weighted percentages).   
 
Baseline characteristics Patients (n=672) 
Age (Median  [Q1-Q3]) 
Age (%) 
75-84 years  
85 and more% 
82 (79-86) 
 
63.9 
36.1 
Gender (%) 
Female 
Male  
 
55.9 
44.1 
Reason for admission (%) 
Acute disease 
Exacerbation of a chronic disease  
 
51.4 
48.6 
Origin (%) 
Emergency room  
Others 
 
93.3 
6.7 
Dwelling (%) 
Community  
Nursing Home  
Others  
 
87.1 
11.5 
1.4 
Living with (%) 
Couple/Family  
Single 
Others  
 
69.5 
14.5 
16.0 
General Practitioner visits during the previous month (%) 
None 
One or two  
Three or more   
 
40.0 
48.3 
11.7 
Admissions during the previous month (%) 
None 
One  
Two or more  
 
85.2 
12.7 
2.1 
Barthel index (Median [Q1-Q3])  
Basal  
On admission 
At discharge  (616 patients) 
 
75 (45-90) 
40 (15-65) 
55 (25-75) 
Reisberg basal (%) 
1-2  
3-5  
6-7  
 
57.3 
31.0 
11.7 
Positive CAM at admission (%) 14.3 
Failures in Pfeiffer test  (Median [Q1-Q3]) (565 patients) 2 (1-4) 
Charlson index (Median [Q1-Q3]) 3 (1-4) 
Multimorbiditya (%) 62.0 
Discharged to (%) 
Home 
Nursing Home  
Died  
Others   
 
75.0 
16.8 
7.2 
1.0 
Q1: 1st quartile; Q3: 3rd quartile; CAM: Confusion Assessment Method 
a
 (≥2 clinical categories in the Polypathological Patient scale) [23] 
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Table 2. The most commonly encountered PIMs and PPO according to the respective instruments.  
Beers-listed PIM 
Condition Drug % 
Independent of diagnoses or 
conditions 
Long-acting benzodiazepines 11.8 
Syncope or falls Short-to intermediate-acting benzodiazepines and tricyclic 
antidepressants  
9.9 
Depression Long-term benzodiazepine use. Sympatholytic agents  8.1 
Blood clotting disorders or 
receiving  anticoagulant therapy  
Aspirin, NSAIDs, dipyridamole, ticlopidine and  clopidogrel 6.6 
Chronic constipation Calcium channel blockers, anticholinergics, and triclyclics 
antidepressants  
6.4 
STOPP-listed PIM 
System Drug % 
Drugs that adversely affect 
those who are prone to falls  
Benzodiazepines 15.0 
Central nervous system Long-term, long-acting benzodiazepines  11.5 
Musculoeskeletal system  Long-term NSAID for relief of mild-moderate joint pain in 
osteoarthritis  
8.5 
Duplicate drug classes   Any regular duplicate drug class prescription 8.3 
Cardiovascular system  Aspirin with no history of coronary, cerebral or 
peripheral arterial symptoms or occlusive arterial 
event  
7.6 
START-listed PPO 
System  Drug % 
Cardiovascular system ACE inhibitor with chronic heart failure.  13.4 
Cardiovascular system Warfarin in the presence of chronic atrial fibrillation  11.2 
Cardiovascular system Statin therapy with a documented history of coronary, 
cerebral or peripheral vascular disease, where the 
patient’s functional status remains independent for 
activities of daily living and life expectancy is > 5 
years.  
8.2 
Musculoeskeletal system  Calcium and vitamin D supplement in patients with 
known osteoporosis (radiological evidence or previous 
fragility fracture or acquired dorsal kyphosis).  
7.6 
Respiratory System  Regular inhaled beta-2 agonist or anticholinergic agent for 
mild to moderate asthma or COPD. 
6.1 
ACOVE3-listed PPO 
Condition Drug % 
Hypertension (HTN) Angiotensin- Converting Enzyme (ACE) inhibitor for 
comorbid vascular disease.  
IF a VE with HTN has a history of Heart Failure (HF), left 
ventricular hypertrophy, IHD, chronic kidney disease, or 
cardiovascular accident, THEN he or she should be treated 
with an ACE inhibitor or Angiotensin – receptor blockers 
(ARB). 
10.8 
Stroke and Atrial Fibrillation  Anticoagulate atrial fibrillation.  
IF a VE has chronic atrial fibrillation and is at medium to high 
risk of stroke, THEN anticoagulation should be offered. 
9.0 
Chronic obstructive pulmonary 
disease (COPD) 
Rapid-acting bronchodilator 
IF a VE has COPD (GOLD Stage >I), THEN he or she should 
be prescribed a rapid-acting bronchodilator.  
8.9 
Osteoporosis Calcium and vitamin D for osteoporosis 
IF a VE has osteoporosis, THEN he or she should be 
prescribed calcium and vitamin D supplements. 
8.5 
Osteoarthritis (OA) First-line pharmacological therapy 
IF a VE is started on pharmacological therapy to treat OA, 
THEN acetaminophen should be tried first.  
8.5 
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Table 3. Independent risk factors associated to Inappropriate Prescribing (IP), Potentially Inappropriate 
Medicines (PIM) and Potentially Prescribing Omissions (PPO). Multivariate logistic regression analysis. 
Risk Factor Global IP (n: 597)  No global IP (n: 75) OR 95% CI 
Gender  
• Female 
• Male  
 
58.71 
41.3 
 
36.19 
63.81 
 
2.36 
1 
 
1.31-4.25 
Number of medicines  
• 10 or more 
• 5-9 
• 0-4 
 
59.12 
36.43 
4.45 
 
32.86 
37.48 
29.66 
 
11.34 
6.00 
1 
 
4.96-25.94 
2.63-13.67 
Risk Factor Global PIM (n: 488)  No global PIM (184) OR 95% CI 
Gender  
• Female  
• Male 
 
59.94 
40.06 
 
44.05 
55.95 
 
1.72 
1 
 
1.12-2.63 
Number of medicines  
• 10 or more 
• 5-9 
• 0-4 
 
62.13 
35.47 
2.4 
 
37.38 
39.77 
22.85 
 
14.16 
7.36 
1 
 
6.44-31.12 
3.34-16.22 
Global PPO 
• Yes  
• No 
 
72.66 
27.34 
 
51.14 
48.86 
 
2.26 
1 
 
1.44-3.56 
Barthel index basal 
• Total dependence  
• Severe dependence  
• Moderate dependence   
• Mild dependence  
• Independence  
 
12.98 
8.62 
19.36 
47.91 
11.12 
 
3.39 
11.11 
22.01 
46.20 
17.29 
 
5.42 
0.75 
0.84 
1.28 
1 
 
1.96-14.98 
0.30-1.83 
0.40-1.74 
0.67-2.46 
Risk Factor Global PPO (483)  No global PPO (189) OR 95% CI 
Multimorbiditya 
• Yes 
• No 
 
67.18 
32.82 
 
51.18 
48.82 
 
1,93 
1 
 
1,25-2,97 
Global PIM 
• Yes 
• No 
 
80.79 
19.21 
 
62.34 
37.66 
 
2,79 
1 
 
1,81-4,28 
Barthel index basal 
• Total dependence  
• Severe dependence  
• Moderate dependence   
• Mild dependence  
• Independence 
 
8.98 
9.06 
22.65 
46.43 
12.88 
 
13.81 
9.64 
14.65 
49.63 
12.27 
 
0.29 
0.52 
0.95 
0.67 
1 
 
0.12-0.68 
0.21-1.24 
0.43-2.07 
0.35-1.28 
 
Dwelling 
• Others 
• Community 
 
14.96 
85.04 
 
8.55 
91.45 
 
2.20 
1 
 
1.14-4.25 
 
Global IP was considered when a patient was prescribed with at least one Beer’s, STOPP, START and/or 
ACOVE criteria. 
Global PIM was considered when at least one Beers and/or STOPP criterion was prescribed, and global PPO, 
when at least one START and/or ACOVE-3 criteria was prescribed. 
a
 (≥2 clinical categories in the Polypathological Patient scale) [23] 
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Table 4. Independent risk factors associated with Beers, STOPP, START and ACOVE3 criteria. Multivariate 
logistic regression analysis. 
 
Risk Factor Beers (n: 317) No Beers (n: 355) OR 95% CI 
Gender 
• Female 
• Male 
 
61.8 
38.2 
 
49.8 
50.2 
 
1.57 
1 
 
1.07-2.3 
Age  
75-84 years 
85 and over 
 
68.28 
31.72 
 
59.35 
40.65 
 
1,53 
1 
 
1.07-2.2 
Number of medicines 
• 10 or more 
• 5-9 
• 0-4 
 
66.42 
31.98 
1.6 
 
44.88 
41.34 
13.79 
 
8.19 
4.71 
1 
 
3.01-22.28 
1.71-12.99 
Risk factor STOPP (n: 414) No STOPP (n: 258) OR 95% CI 
Multimorbiditya 
• Yes 
• No 
 
63.54 
36.46 
 
59.38 
40.62 
 
0.57 
1 
 
0.36-0.92 
Number of medicines 
• 10 or more 
• 5-9 
• 0-4 
 
64.17 
33.45 
2.38 
 
42.71 
41.49 
15.79 
 
8.21 
4.13 
1 
 
3.47-19.44 
1.74-9.78 
Barthel index basal 
• Total dependence  
• Severe dependence  
• Moderate dependence   
• Mild dependence  
• Independence 
 
13.07 
8.22 
19.35 
49.06 
10.3 
 
6.58 
10.89 
21.1 
44.98 
16.45 
 
3.79 
1.1 
1.33 
1.68 
1 
 
1.5-9.54 
0.46-2.63 
0.62-2.84 
0.86-3.3 
ACOVE3 criteria 
• yes 
• No 
 
65.63 
34.37 
 
41.94 
58.06 
 
2.68 
1 
 
1.77-4.06 
Risk Factor START (n: 374) No START (298) OR 95% CI 
Multimorbidity 
• Yes 
• No 
 
70.53 
29.47 
 
52.88 
47.12 
 
1.76 
1 
 
1.14-2.7 
Global PIM  
• Yes 
• No 
 
56.01 
43.99 
 
37.38 
62.62 
 
1.6 
1 
 
1.02-2.51 
Dwelling 
• Others  
• Community 
 
16.77 
83.23 
 
8.75 
91.25 
 
1.82 
1 
 
1.02-3.24 
Risk Factor ACOVE3 (n: 418) No ACOVE3 (n: 254) OR 95% CI 
STOPP criteria 
• Yes 
• No 
 
71.29 
28.71 
 
48.44 
51.56 
 
2.3 
1 
 
1.51-3.49 
 
a
 (≥2 clinical categories in the Polypathological Patient scale) [23] 
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Figure 1. Distribution of patients into the groups of inappropriate prescribing (weighted percentages). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IP: Inappropriate Prescribing, PIM: Potentially Inappropriate Medicines; PPO:  Potentially  Prescribing 
Omissions  
Global IP was considered when a patient was prescribed with at least one Beer’s, STOPP, START and/or 
ACOVE criteria. 
Global PIM was considered when at least one Beers and/or STOPP criterion was prescribed, and global PPO, 
when at least one START and/or ACOVE-3 criteria was prescribed. 
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